|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-2-21
|
|
pubmed:abstractText |
In a multicenter trial, 259 young adults (15-49 years) with newly diagnosed acute myeloid leukemia (AML) were first randomized to receive a timed-sequential induction regimen given either alone (135 patients) or concomitantly with granulocyte-macrophage colony-stimulating factor (GM-CSF) (124 patients). Patients reaching complete remission (CR) were then randomized to compare a timed-sequential consolidation to a postremission chemotherapy including four cycles of high-dose cytarabine followed by maintenance courses. In the appropriate arm, GM-CSF was given concurrently with chemotherapy during all cycles of consolidation. CR rates were significantly better in the GM-CSF arm (88 vs 78%, P<0.04), but did not differ after salvage. Patients receiving GM-CSF had a higher 3-year event-free survival (EFS) estimate (42 vs 34%), but GM-CSF did not impact on overall survival. Patients with intermediate-risk cytogenetics benefited more from GM-CSF therapy (P=0.05) in terms of EFS than patients with other cytogenetics. This was also confirmed when considering only patients following the second randomization, or subgroups defined by a prognostic index based on cytogenetics and the number of courses required for achieving CR. Priming of leukemic cells with hematopoietic growth factors is a means of enhancing the efficacy of chemotherapy in younger adults with AML.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0887-6924
|
|
pubmed:author |
pubmed-author:ArnaudPP,
pubmed-author:BottonS deS,
pubmed-author:BourhisJ-HJH,
pubmed-author:CastaigneSS,
pubmed-author:CordonnierCC,
pubmed-author:CorrontBB,
pubmed-author:DombretHH,
pubmed-author:ElhamriMM,
pubmed-author:FenauxPP,
pubmed-author:GardinCC,
pubmed-author:LeQ-HQH,
pubmed-author:MichalletMM,
pubmed-author:PautasCC,
pubmed-author:PreudhommeCC,
pubmed-author:QuesnelBB,
pubmed-author:RaffouxEE,
pubmed-author:RemanOO,
pubmed-author:TervoAA,
pubmed-author:ThomasXX,
pubmed-author:de RevelTT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
453-61
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17252021-Acute Disease,
pubmed-meshheading:17252021-Adolescent,
pubmed-meshheading:17252021-Adult,
pubmed-meshheading:17252021-Amsacrine,
pubmed-meshheading:17252021-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17252021-Cell Division,
pubmed-meshheading:17252021-Combined Modality Therapy,
pubmed-meshheading:17252021-Cytarabine,
pubmed-meshheading:17252021-Daunorubicin,
pubmed-meshheading:17252021-Disease-Free Survival,
pubmed-meshheading:17252021-Drug Administration Schedule,
pubmed-meshheading:17252021-Female,
pubmed-meshheading:17252021-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:17252021-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:17252021-Humans,
pubmed-meshheading:17252021-Kaplan-Meier Estimate,
pubmed-meshheading:17252021-Leukemia, Myeloid,
pubmed-meshheading:17252021-Male,
pubmed-meshheading:17252021-Middle Aged,
pubmed-meshheading:17252021-Mitoxantrone,
pubmed-meshheading:17252021-Neoplastic Stem Cells,
pubmed-meshheading:17252021-Premedication,
pubmed-meshheading:17252021-Proportional Hazards Models,
pubmed-meshheading:17252021-Recombinant Proteins,
pubmed-meshheading:17252021-Risk,
pubmed-meshheading:17252021-Salvage Therapy,
pubmed-meshheading:17252021-Stimulation, Chemical,
pubmed-meshheading:17252021-Transplantation, Homologous,
pubmed-meshheading:17252021-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
|
|
pubmed:affiliation |
Department of Hematology, Hôpital Edouard Herriot, Lyon, France. xavier.thomas@chu-lyon.fr
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
